⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Volumetryx and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Volumetryx
↗Montreal, Canada
Volumetryx is a specialized oncology imaging CRO (Contract Research Organization) founded in 2024. The company provides a SaaS-based platform called BioSUITE, designed to give early-stage oncology trial sponsors full control over their imaging data, including DICOM ownership, without the high costs associated with traditional enterprise imaging CROs.
The company's core services include a 'Collect & Hold' platform for data management, advanced volumetric tumor analysis (such as MTV, TLG, and viable tumor volume), and blinded central reads by oncology subspecialist radiologists. Volumetryx focuses on streamlining the imaging workflow for Phase I and II oncology trials, offering rapid setup and fast turnaround times for reads.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Seed
PIPELINE
Stage:Commercial
Modalities:PET/CT, MRI, CT
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
Competitors:Traditional Imaging CROs
LEADERSHIP
Key Executives:
Vlad Cherniavsky - CEO & Co-founder
Kateryna Musaieva - CMO & Co-founder
Burkhan Musaiev - VP Oncology Imaging & Co-founder
Ilya Kalyzhniuk - Co-founder
Scientific Founders:Kateryna Musaieva, Burkhan Musaiev
LINKS
Website:volumetryx.ai
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Volumetryx. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.